Unlocking value potential for a client’s rare disease treatment
In this use case, learn how MMIT, powered by NorstellaLinQ, translated complex RWD into actionable strategies to help the client achieve business growth while advancing equity and patient access.
Addressing cost barriers and enhancing medicare access strategies to improve commercialization strategy
In this use case, learn how MMIT, powered by NorstellaLinQ, translated complex RWD into actionable insights which helped the client tackle affordability and access challenges in a complex therapeutic area.
Innovation trends from R&D to market access
2024 has been an incredibly busy year for Norstella as its constituent organizations – Citeline, Evaluate, MMIT, Panalgo, and the Dedham Group – have continued to support the biopharma ecosystem in bringing new therapies to patients. Throughout the course of the year, we have also shared our latest views on the issues that are most […]
Assessing AI transformation in pharma R&D: Current and future impact
Artificial intelligence (AI) has been one of the largest disruptors in drug development over the past few years, with the promise of innovation and greater efficiencies keeping the pharma industry heavily invested. There have been major advancements in AI-discovered molecules and AI-powered platforms for decentralized treatment, in addition to many more AI applications that have […]
Conference catch-up: Collaboration and innovation in biopharma
The biopharma industry is evolving, with increased focus on partnerships, early-phase deal-making and technologies like AI and machine learning. At this year’s BIO-Europe conference in Stockholm, Norstella’s subject matter experts joined discussions on key topics, including a roundtable on the future of precision medicine and a panel on the pharma patent cliff, highlighting the role […]